Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Carcinoma, Hepatocellular
  • Liver Neoplasms

abstract

  • We observed significant clinical and biologic activity for bevacizumab in nonmetastatic HCC and achieved the primary study end point. Serious bleeding complications occurred in 11% of patients. Further evaluation is warranted in carefully selected patients.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3635806

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.15.9947

PubMed ID

  • 18565886

Additional Document Info

start page

  • 2992

end page

  • 8

volume

  • 26

number

  • 18